Combining therapies to address broader need
Description
SparingVision intends to evaluate the potential therapeutic synergy of its two lead products through the combination of SPVN06 and SPVN20 as a single construct, called SPVN30, to address a broader population of patients.
Development plan
SPVN30 is at a non-clinical stage, where SparingVision is testing the synergies between the RdCVF/L and GIRK technologies and evaluating the technical feasibility of a new gene therapy program.
PARTNERS
